AMA holds steady on MU stance

The American Medical Association (AMA) continues to call for the governmnt to halt penalties in the Meaningful Use (MU) program, saying that full interoperability, which is not widely available, is necessary to achieve the goals of EHRs.

In response to the low number of organizations that have successfully attested to Stage 2, AMA joined with other organizations to urge policymakers to take immediate action to fix the MU program by adding more flexibility and shortening the reporting period to help physicians avoid penalties.    

“The AMA has been calling for policymakers to refocus the Meaningful Use program on interoperability for quite some time,” said AMA President-elect Steven J. Stack, MD, in a release. “The whole point of the Meaningful Use incentive program was to allow for the secure exchange of information across settings and providers and right now that type of sharing and coordination is not happening on a wide scale for reasons outside physicians’ control. Physicians want to improve the quality of care and usable, interoperable electronic health records are a pathway to achieving that goal.”

The organization also cited certification of products and the cost of those certified products as a challenge for physicians trying to meet MU requirements. "The extensive amount of time it takes for vendors to develop new, mandatory elements of EHRs and the lack of flexibility in the certification process are leading to late deliveries. That makes it impossible for many physicians to report for the whole year, a requirement for receiving an incentive," according to the release. And, vendors must first focus on MU development requirements rather than meeting physicians' needs.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.